Chicago - The promise of biochemotherapy for stage IV malignant melanoma has not held up to scrutiny, and the value of this form of treatment seems nil, according to recent discouraging findings from major phase III clinical trials.
Reviewing Late-Breaking Research From AAD 2024
ReV Up Your Vitiligo Treatment Strategies
Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Melanoma and the Wrong Site
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy